SmithKline Beecham in major restenosis trial
This article was originally published in Clinica
Executive Summary
Anglo-American pharmaceutical company SmithKline Beecham is conducting the largest ever trial in the prevention of restenosis following angioplasty. The trial, known as PRESTO, is comparing SB's agent, tranilast (licensed from Japanese company Kissei), with placebo in 11,500 patients.